Realcan Pharmaceutical Group Co., Ltd.

002589

CNE1000013X5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
2.21 ^CNY	-0.45%		+0.45%	-32.42%

28/05	Realcan Pharmaceutical Group Co., Ltd. Implements 2023 Final Profit Distribution for A Shares, Payable on 04 June 2024	CI
22/05	Shenzhen New Nanshan Holding Co., Ltd. Approves Cash Dividend for the Year 2023	CI

Shanghai Haixin Pharmaceuticals Co.,Ltd. cancelled the transaction announced on December 18, 2017

January 05, 2018

On January 5, 2018, cancelled the transaction. The transaction was rejected by the shareholders of the company at its 1st extraordinary general meeting.

Latest news about Realcan Pharmaceutical Group Co., Ltd.

Realcan Pharmaceutical Group Co., Ltd. Implements 2023 Final Profit Distribution for A Shares, Payable on 04 June 2024	29/05	CI
Shenzhen New Nanshan Holding Co., Ltd. Approves Cash Dividend for the Year 2023	22/05	CI
Realcan Pharmaceutical Group Co., Ltd. Proposes the Profit Distribution for 2023	30/04	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) added to S&P Global BMI Index	18/23/18	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Realcan Pharmaceutical Group Co., Ltd. Approves the Executive Appointments	23/23/23	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Shanghai Pharmaceutical Co., Ltd. entered into an agreement to acquire 51% stake in Hunan Runji Pharmaceutical Co., Ltd. from Realcan Pharmaceutical Group Co., Ltd. for CNY 149 million	17/23/17	CI
Realcan Pharmaceutical Group Co., Ltd. agreed to acquire 9.6409% of Shandong Lekang Jinyue Industrial Co., Ltd. from Yantai Chenghou Investment Co., Ltd for CNY 84.84 million.	16/22/16	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/22/30	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Realcan Pharmaceutical Group Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on July 22, 2022	15/22/15	CI
Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) dropped from S&P Global BMI Index	20/22/20	CI
Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2021	25/22/25	CI
Realcan Pharmaceutical Group Co., Ltd. Announces Profit Distribution Proposal for 2021	06/22/06	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/22/29	CI
Realcan Pharmaceutical Group Co., Ltd. agreed to acquire a 38.39992% stake in Tianjin Guohui Big Health Technology Co., Ltd. from Yantai Huishuo Enterprise Management Partnership Enterprise for approximately CNY 230 million.	18/22/18	CI
Realcan Pharmaceutical Group Co., Ltd. acquired Health Technology for approximately CNY 230 million.	17/22/17	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/21/29	CI
Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) dropped from FTSE All-World Index	20/21/20	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	30/21/30	CI
Realcan Pharmaceutical Group Co., Ltd. Announces Cash Dividend on A Shares for the Year 2020, Payable on June 23, 2021	18/21/18	CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	29/21/29	CI

Chart Realcan Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Realcan Pharmaceutical Group Co., Ltd.

More charts

Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
REALCAN PHARMACEUTICAL GROUP CO., LTD.	-32.42%	46Cr
MCKESSON CORPORATION	+26.13%	7.57TCr
CARDINAL HEALTH, INC.	-5.35%	2.32TCr
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+15.24%	876.35Cr
SINOPHARM GROUP CO. LTD.	-6.50%	768.25Cr
HUADONG MEDICINE CO., LTD	-33.02%	669.09Cr
H. LUNDBECK A/S	+19.54%	557.59Cr
GALENICA AG	+3.99%	422.37Cr
EBOS GROUP LIMITED	-3.66%	399.32Cr
MEDIPAL HOLDINGS CORPORATION	+14.24%	339.28Cr

Pharmaceuticals Wholesale

Realcan Pharmaceutical Group Co., Ltd.

Equities

002589

CNE1000013X5

Pharmaceuticals

Shanghai Haixin Pharmaceuticals Co.,Ltd. cancelled the transaction announced on December 18, 2017

Latest news about Realcan Pharmaceutical Group Co., Ltd.

Chart Realcan Pharmaceutical Group Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Pharmaceuticals Wholesale